

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Keymed Biosciences Inc.
康諾亞生物醫藥科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2162)

VOLUNTARY ANNOUNCEMENT

THE LATEST DATA FROM THE PHASE I/II CLINICAL STUDY OF CM336 AT THE 66TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING BY WAY OF A POSTER

This announcement is made by Keymed Biosciences Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company is pleased to announce that the latest data of its phase I/II clinical study of CM336, a bispecific antibody targeting B-cell maturation antigen (BCMA)×CD3, for relapsed or refractory multiple myeloma was presented as a poster at the 66th American Society of Hematology (ASH) Annual Meeting.

The phase I/II clinical study was designed to assess the safety, tolerability, and preliminary efficacy of CM336 in patients with relapsed or refractory multiple myeloma. As of October 30, 2024, a total of 68 patients were enrolled in this study (25 in the dose-escalation phase and 43 in the dose-expansion phase). All patients had received prior proteasome inhibitors, immunomodulators, and anti-CD38 monoclonal antibody. The median number of prior lines of therapy was four.

In terms of safety, CM336 had a manageable safety and tolerability profile. Patients received CM336 at dose levels up to 160 mg, and the maximum tolerated dose was not reached. The most common treatment-emergent adverse events were cytokine release syndrome (CRS), lymphocyte count decreased, and anaemia. Most events of CRS were grade 1, and only 7% (5/68) of patients experienced grade 2 CRS. No immune effector cell-associated neurotoxicity syndrome occurred.

In the dose-escalation phase, with a median follow-up of 12.1 months, 52% (12/23) of patients achieved stringent complete response (sCR) or complete response (CR). In dose-escalation and expansion phases, with a median follow-up of 3.1 months, the overall response rate (ORR) was 67% (16/24) and 76% (19/25) for the 3/20/80 mg and 3/20/80/160 mg dose groups, respectively. Several patients have not achieved the best overall response. Of the 19 patients evaluable for minimal residual disease (MRD), MRD negativity rate was 95% (18/19), and the median time to MRD-negative response was 2.1 months.

CM336 showed a favorable safety and tolerability profile in this study. CM336 demonstrated preliminary efficacy in patients with relapsed or refractory multiple myeloma.

About CM336

CM336, an anti-BCMA×CD3 bispecific antibody, simultaneously targets both BCMA on target cells and CD3 receptor on T cells, facilitating the recruitment of immune T cells to the vicinity of target cells. This interaction induces T-cell-dependent cellular cytotoxicity (TDCC) to eliminate target cells.

As of the date of this announcement, this multicenter, open-label phase I/II clinical study evaluating CM336 injection in patients with relapsed or refractory multiple myeloma is ongoing. Furthermore, based on the clinical efficacy observed in multiple myeloma, the Company believes that CM336 is a promising novel therapeutic option for autoimmune diseases by eliminating plasma cells that secrete pathogenic antibodies.

This announcement is made by the Company on a voluntary basis to provide information to shareholders and potential investors of the Company. There is no assurance that CM336 will ultimately develop, launch and/or commercialize successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Keymed Biosciences Inc.
Dr. Bo CHEN
Chairman

Hong Kong, December 9, 2024

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive Directors; Mr. Qi CHEN, Dr. Min Chuan WANG and Mr. Yilun LIU as non-executive Directors; Prof. Xiao-Fan WANG, Prof. Yang KE and Mr. Cheuk Kin Stephen LAW as independent non-executive Directors.